At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 47 enrolled
Drug / intervention
cediranib maleatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of AZD2171 in Patients With Recurrent Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
In Brief
A Phase 2 clinical trial evaluating cediranib maleate for Fallopian Tube Cancer and 4 related conditions. Completed, enrolled 47 participants across 1 site.
Detailed Summary
This phase II trial is studying how well AZD2171 works in treating patients with recurrent ovarian, peritoneal, or fallopian tube cancer. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma, Recurrent Ovarian Epithelial Cancer, Stage I Ovarian Epithelial Cancer, Stage II Ovarian Epithelial Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedJan 2006
Primary CompletionMar 2010
Study CompletionJan 2011
TodayJul 2026
First PostedJan 11, 2006
Enrollment StartOct 1, 2005
Primary CompletionMar 1, 2010
Study CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 20.5 years ago
Interventions
cediranib maleatedrug
Given orally